Budget constraints will have an increasing focus as FDA makes strategic decisions in the coming years.
Agency officials included stewardship, such as doing more with less funding, among the cross-cutting strategic priorities in its draft
“Given the limited availability of investment capital for medical product development, early clarification of regulatory requirements is critical,” FDA says. Agency officials included stewardship, such as doing more with less funding, among the cross-cutting strategic priorities in its draft strategic priorities document for 2014-2018.
Budget constraints will have an increasing focus as FDA makes strategic decisions in the coming years.
Agency officials included stewardship, such as doing more with less funding, among the cross-cutting strategic priorities in its draft